Please note that slides are for review only and not to be repurposed or published.

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Colorectal, Gastroesophageal and Pancreatic Cancer

MODULE 1:
The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster

MODULE 2:
Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall

MODULE 3:
Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman

MODULE 4:
Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger

Module 5:
Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip

Module 6:
PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Hepatobiliary Cancers

MODULE 1:
First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC) — Dr Finn

MODULE 2:
Available Data with and Patient Selection for Anti-angiogenic Therapy for Progressive Metastatic HCC — Dr Zhu

MODULE 3:
Published Data with and Appropriate Integration of Immune Checkpoint Inhibitors into the Care of Patients with Progressive Metastatic HCC — Dr El-Khoueiry

MODULE 4:
Novel Approaches Under Investigation for Advanced HCC — Prof Galle

Module 5:
Current and Future Management of Advanced Biliary Tract Cancers — Dr Abou-Alfa